ROTIGOTINE-CONTAINING PERCUTANEOUSLY-ABSORBABLE PATCH PREPARATION WITH INHIBITED PHOTOLYSIS OF AGENT
PROBLEM TO BE SOLVED: To provide a rotigotine-containing percutaneously-absorbable patch preparation that can inhibit photolysis of rotigotine with light, without using an aluminum-containing film as a support.SOLUTION: A percutaneously-absorbable patch preparation has a support, an agent-containing...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | PROBLEM TO BE SOLVED: To provide a rotigotine-containing percutaneously-absorbable patch preparation that can inhibit photolysis of rotigotine with light, without using an aluminum-containing film as a support.SOLUTION: A percutaneously-absorbable patch preparation has a support, an agent-containing adhesive layer, and a release liner. The support is an aluminum-free support in which a transmittance of light with a wavelength of 310 nm-370 nm is 40% or less. The agent is rotigotine or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: Figure 4
【課題】支持体としてアルミニウム含有フィルムを使用せずに、光によるロチゴチンの分解を抑制可能なロチゴチン含有経皮吸収型貼付製剤を提供すること。【解決手段】支持体、薬物含有粘着剤層及び剥離ライナーからなる経皮吸収型貼付製剤であって、支持体が、波長３１０ｎｍ〜３７０ｎｍの光線透過率が４０％以下であるアルミニウム不含支持体であり、薬物がロチゴチン又はその製薬上許容される塩である経皮吸収型貼付製剤。【選択図】 図４ |
|---|